サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1421656

膣炎治療薬市場、シェア、規模、動向、産業分析レポート：疾患タイプ別、製品別、地域別、およびセグメント別予測、2023年～2032年

Vaginitis Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Anti-fungal, Anti-bacterial, Hormone); By Product (OTC, Prescription); By Region, And Segment Forecasts, 2023 - 2032

出版日
ページ情報
英文 114 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
膣炎治療薬市場、シェア、規模、動向、産業分析レポート：疾患タイプ別、製品別、地域別、およびセグメント別予測、2023年～2032年
出版日: 2023年11月23日
発行: Polaris Market Research
ページ情報: 英文 114 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の膣炎治療薬市場規模は2032年までに72億米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

政府・非政府を問わず、複数の組織が膣炎治療薬に関する女性の意識向上を目的としたプログラムを開始しており、これがこれらの治療薬の需要増につながっています。さらに、アルコール消費の動向は、これらの薬剤の採用をさらに促進すると予想されます。特に米国では、約530万人の女性が膣炎による健康関連の問題の危険にさらされています。

また、膣炎治療薬の研究開発への注目が高まっていることも、市場の成長に寄与すると予想されます。米国国立アレルギー感染症研究所（NIAID）などの組織が資金を提供する様々な研究により、イースト菌の発生行動に関する貴重な洞察が得られており、イースト菌感染症の革新的な治療アプローチにつながる可能性があります。さらに、大手製薬会社による新薬のイントロダクションが市場拡大の原動力となることが予測され、業界にとって明るい動向を示しています。

プロバイオティクス療法は、カンジダ膣炎に対する現在の治療結果が満足のいくものでないこともあり、最近大きな調査関心を集めています。カンジダ膣炎に最もよく使用される抗真菌薬には、クロトリマゾール、フルコナゾール、ミコナゾール、ナイスタチンなどがあります。しかし、これらの薬剤の中には、真菌の増殖を抑制するだけで、真菌を完全に駆除できないものもあります。また、長期にわたる使用は、正常な腟の細胞や組織に害を及ぼし、局所的な腟の微生物叢の不均衡、酸塩基平衡の乱れ、超感染症、再発性感染症などを引き起こす可能性があります。従って、膣の微小環境を制御できるカンジダ膣炎の治療法を探求することが急務です。

機能解析の結果、ヒアルロン酸ハイドロゲルにナノザイムを組み合わせると、過酸化水素濃度が低くてもカンジダ・アルビカンスを効果的に駆除できることが示されました。ナノザイムと乳酸菌を組み合わせると、カンジダ膣炎治療中の真菌の生存率が70％有意に減少しました。対照的に、乳酸菌を単独で使用した場合は、真菌の生存率に影響を与えなかった。詳細な分析により、ナノザイムと乳酸菌の併用は、ヒドロキシラジカルを発生させるのに極めて効率的であり、真菌の細胞膜に実質的な損傷を与えることが実証されました。特筆すべきは、この併用処理は乳酸菌に悪影響を及ぼさなかったことです。

米国疾病予防管理センター（CDC）の性感染症（STI）治療ガイドラインによれば、症状のあるBV患者にはメトロニダゾールを1日2回7日間経口投与するか、毎日5日間膣内投与するか、クリンダマイシンゲルを7日間膣内投与します。調査によると、メトロニダゾールの経口投与は再発性BV患者に膣内マイクロバイオームの一時的な改善をもたらすが、治療後30日目までに再発します。別の研究では、初回治療後、膣内ベンズニダゾール（IBA）療法とニトロイミダゾール療法による治癒率が高いことが示されています。

膣炎治療薬市場レポートハイライト

  • 抗菌薬セグメントは、幅広い製品群の入手可能性と細菌性膣炎の患者数の増加により、市場を独占
  • ホルモン分野は、製品パイプラインの存在と開業医の間での採用により、急速なペースで成長すると思われます。
  • 北米は、主に膣炎の症例数の増加と患者の意識向上により、市場を独占しています。
  • 主な市場プレイヤーは、ファイザー、メルク、ノバルティス、バイエル、ルピン・ファーマシューティカルズ、シンビオミックス・セラピューティクス、ミッション・ファーマカルなどです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の膣炎治療薬市場に関する洞察

  • 膣炎治療薬市場- 業界スナップショット
  • 膣炎治療薬市場力学
    • 促進要因と機会
      • 女性の健康に対する意識と教育の向上
      • 診断と治療の選択肢における技術の進歩
    • 抑制要因と課題
      • 抗生物質および抗真菌薬に対する耐性
  • PESTLE分析
  • 膣炎治療薬業界の動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の膣炎治療薬市場、疾患タイプ別

  • 主な調査結果
  • イントロダクション
  • 抗真菌
  • 抗菌
  • ホルモン

第6章 世界の膣炎治療薬市場、製品別

  • 主な調査結果
  • イントロダクション
  • 店頭販売（OTC）
  • 処方箋

第7章 世界の膣炎治療薬市場、地域別

  • 主な調査結果
  • イントロダクション
    • 膣炎治療薬市場評価、地域別、2019-2032年
  • 膣炎治療薬市場-北米
    • 北米：膣炎治療薬市場、製品別、2019-2032年
    • 北米：膣炎治療薬市場、疾患タイプ別、2019～2032年
    • 膣炎治療薬市場-米国
    • 膣炎治療薬市場- カナダ
  • 膣炎治療薬市場- 欧州
    • 欧州：膣炎治療薬市場、製品別、2019～2032年
    • 欧州：膣炎治療薬市場、疾患タイプ別、2019～2032年
    • 膣炎治療薬市場- 英国
    • 膣炎治療薬市場- フランス
    • 膣炎治療薬市場- ドイツ
    • 膣炎治療薬市場- イタリア
    • 膣炎治療薬市場- スペイン
    • 膣炎治療薬市場- オランダ
    • 膣炎治療薬市場- ロシア
  • 膣炎治療薬市場- アジア太平洋
    • アジア太平洋地域：膣炎治療薬市場、製品別、2019～2032年
    • アジア太平洋地域：膣炎治療薬市場、疾患タイプ別、2019～2032年
    • 膣炎治療薬市場- 中国
    • 膣炎治療薬市場- インド
    • 膣炎治療薬市場- マレーシア
    • 膣炎治療薬市場- 日本
    • 膣炎治療薬市場- インドネシア
    • 膣炎治療薬市場- 韓国
  • 膣炎治療薬市場-中東およびアフリカ
    • 中東およびアフリカ：膣炎治療薬市場、製品別、2019～2032年
    • 中東およびアフリカ：膣炎治療薬市場、疾患タイプ別、2019～2032年
    • 膣炎治療薬市場- サウジアラビア
    • 膣炎治療薬市場- アラブ首長国連邦
    • 膣炎治療薬市場- イスラエル
    • 膣炎治療薬市場- 南アフリカ
  • 膣炎治療薬市場-ラテンアメリカ
    • ラテンアメリカ：膣炎治療薬市場、製品別、2019-2032年
    • ラテンアメリカ：膣炎治療薬市場、疾患タイプ別、2019～2032年
    • 膣炎治療薬市場- メキシコ
    • 膣炎治療薬市場- ブラジル
    • 膣炎治療薬市場- アルゼンチン

第8章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Pfizer, Inc.
  • Merck & Co.
  • Novartis AG
  • Bayer AG
  • Lupin Pharmaceuticals, Inc.
  • Symbiomix Therapeutics, Inc.
  • Mission Pharmacal Company
図表

List of Tables

  • Table 1 Global Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 2 Global Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 3 Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 5 North America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 7 U.S.: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 8 Canada: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 9 Canada: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 10 Europe: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 11 Europe: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 12 UK: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 13 UK: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 14 France: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 15 France: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 16 Germany: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 17 Germany: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 18 Italy: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 19 Italy: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 20 Spain: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 21 Spain: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 24 Russia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 25 Russia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 28 China: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 29 China: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 30 India: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 31 India: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 34 Japan: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 35 Japan: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 39 South Korea: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 44 UAE: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 45 UAE: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 46 Israel: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 47 Israel: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 49 South Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 51 Latin America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 53 Mexico: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 55 Brazil: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • Table 57 Argentina: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Vaginitis Therapeutics Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Product
  • Figure 7 Global Vaginitis Therapeutics Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Disease Type
  • Figure 9 Global Vaginitis Therapeutics Market, by Disease Type, 2022 & 2032 (USD Billion)
  • Figure 10 Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Vaginitis Therapeutics Market
目次
Product Code: PM3987

The global vaginitis therapeutics market size is expected to reach USD 7.20 billion by 2032, according to a new study by Polaris Market Research. The report "Vaginitis Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Anti-fungal, Anti-bacterial, Hormone); By Product (OTC, Prescription); By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Several organizations, both governmental and non-governmental, have initiated programs aimed at creating awareness among women regarding vaginitis drugs, which has led to an increased demand for these drugs. Furthermore, the rising trend of alcohol consumption is expected to further boost the adoption of these drugs. Notably, in the United States, about 5.3 million women are at risk of health-related issues due to vaginitis.

In addition, the increasing focus on research and development of vaginitis therapeutics is expected to contribute to the growth of the market. Various studies funded by organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) have yielded valuable insights into yeast generative behavior, which could lead to innovative treatment approaches for yeast infections. Moreover, the introduction of new medications by major pharmaceutical companies is projected to drive the market expansion, indicating a positive trend for the industry.

Probiotic therapy has gained significant research attention recently, in part due to the unsatisfactory outcomes of current treatments for Candida vaginitis. The most commonly used antifungal drugs for Candida vaginitis include Clotrimazole, Fluconazole, Miconazole, and Nystatin. However, some of these drugs only inhibit fungal growth without eradicating them entirely. Prolonged use can also harm normal vaginal cells and tissues, leading to imbalances in local vaginal microbiota, disruptions in acid-base balance, superinfections, and recurrent infections. Therefore, there is an urgent need to explore therapies for Candida vaginitis that can regulate the vaginal microenvironment.

Functional analysis has shown that when hyaluronic acid hydrogel is combined with nanozymes, it effectively eradicates Candida albicans even at lower hydrogen peroxide concentrations. Combining nanozymes with Lactobacillus led to a significant 70% reduction in fungal viability during Candida vaginitis treatment. In contrast, using Lactobacillus alone did not demonstrate any impact on fungal viability. In-depth analysis demonstrated that the joint application of nanozymes and Lactobacillus is remarkably efficient in producing hydroxyl radicals, causing substantial damage to the fungal cell membrane. Notably, this combination treatment did not adversely affect the Lactobacillus bacteria.

According to the Centers for Disease Control and Prevention (CDC), symptomatic BV patients should be treated with metronidazole, either orally twice a day for seven days, intravaginally daily for five days, or clindamycin gel intravaginally for seven days, as per their guidelines on sexually transmitted infections (STI) treatment. Research has shown that oral metronidazole provides temporary improvement in the vaginal microbiome for recurrent BV patients, but recurrence occurs by day 30 after therapy. Another study indicated that after initial treatment, the cure rate with Intravaginal Benznidazole (IBA) and nitroimidazole therapy was higher.

Vaginitis Therapeutics Market Report Highlights

  • The anti-bacterial segment dominated the market owing to the availability of a wide product range and rising number of bacterial vaginosis cases
  • The hormone segment will grow at a rapid pace due to the presence of a pipeline of products and adoption among medical practitioners
  • North America dominated the market, primarily due to rising cases of vaginitis and awareness among patient
  • The key market players include Pfizer, Merck, Novartis, Bayer, Lupin Pharmaceuticals, Symbiomix Therapeutics, and Mission Pharmacal.

Polaris Market Research has segmented the vaginitis therapeutics market report based on disease type, product, and region:

Viginitis Therapeutics, Disease Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Anti-fungal
  • Anti-bacterial
  • Hormone

Viginitis Therapeutics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • Over-the-counter (OTC)
  • Prescription

Viginitis Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Vaginitis Therapeutics Market Insights

  • 4.1. Vaginitis Therapeutics Market - Industry Snapshot
  • 4.2. Vaginitis Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing awareness and education on women's health
      • 4.2.1.2. Technological advancements in diagnosis and treatment options
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Resistance to antibiotics and antifungal medications
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Vaginitis Therapeutics Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Vaginitis Therapeutics Market, by Disease Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Vaginitis Therapeutics, by Disease Type, 2019-2032 (USD Billion)
  • 5.3. Anti-fungal
    • 5.3.1. Global Vaginitis Therapeutics Market, by Anti-fungal, by Region, 2019-2032 (USD Billion)
  • 5.4. Anti-bacterial
    • 5.4.1. Global Vaginitis Therapeutics Market, by Anti-bacterial, by Region, 2019-2032 (USD Billion)
  • 5.5. Hormone
    • 5.5.1. Global Vaginitis Therapeutics Market, by Hormone, by Region, 2019-2032 (USD Billion)

6. Global Vaginitis Therapeutics Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
  • 6.3. Over-the-counter (OTC)
    • 6.3.1. Global Vaginitis Therapeutics Market, by Over-the-counter (OTC), by Region, 2019-2032 (USD Billion)
  • 6.4. Prescription
    • 6.4.1. Global Vaginitis Therapeutics Market, by Prescription, by Region, 2019-2032 (USD Billion)

7. Global Vaginitis Therapeutics Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Vaginitis Therapeutics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Vaginitis Therapeutics Market - North America
    • 7.3.1. North America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.2. North America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.3.3. Vaginitis Therapeutics Market - U.S.
      • 7.3.3.1. U.S.: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.3.4. Vaginitis Therapeutics Market - Canada
      • 7.3.4.1. Canada: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.4. Vaginitis Therapeutics Market - Europe
    • 7.4.1. Europe: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.3. Vaginitis Therapeutics Market - UK
      • 7.4.3.1. UK: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.4. Vaginitis Therapeutics Market - France
      • 7.4.4.1. France: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.5. Vaginitis Therapeutics Market - Germany
      • 7.4.5.1. Germany: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.6. Vaginitis Therapeutics Market - Italy
      • 7.4.6.1. Italy: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.7. Vaginitis Therapeutics Market - Spain
      • 7.4.7.1. Spain: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.8. Vaginitis Therapeutics Market - Netherlands
      • 7.4.8.1. Netherlands: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.4.9. Vaginitis Therapeutics Market - Russia
      • 7.4.9.1. Russia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.5. Vaginitis Therapeutics Market - Asia Pacific
    • 7.5.1. Asia Pacific: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.3. Vaginitis Therapeutics Market - China
      • 7.5.3.1. China: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.4. Vaginitis Therapeutics Market - India
      • 7.5.4.1. India: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.5. Vaginitis Therapeutics Market - Malaysia
      • 7.5.5.1. Malaysia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.6. Vaginitis Therapeutics Market - Japan
      • 7.5.6.1. Japan: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.7. Vaginitis Therapeutics Market - Indonesia
      • 7.5.7.1. Indonesia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.5.8. Vaginitis Therapeutics Market - South Korea
      • 7.5.8.1. South Korea: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.6. Vaginitis Therapeutics Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.6.3. Vaginitis Therapeutics Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.6.4. Vaginitis Therapeutics Market - UAE
      • 7.6.4.1. UAE: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.6.5. Vaginitis Therapeutics Market - Israel
      • 7.6.5.1. Israel: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.6.6. Vaginitis Therapeutics Market - South Africa
      • 7.6.6.1. South Africa: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
  • 7.7. Vaginitis Therapeutics Market - Latin America
    • 7.7.1. Latin America: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.7.3. Vaginitis Therapeutics Market - Mexico
      • 7.7.3.1. Mexico: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.7.4. Vaginitis Therapeutics Market - Brazil
      • 7.7.4.1. Brazil: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)
    • 7.7.5. Vaginitis Therapeutics Market - Argentina
      • 7.7.5.1. Argentina: Vaginitis Therapeutics Market, by Product, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Vaginitis Therapeutics Market, by Disease Type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Pfizer, Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Merck & Co.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Novartis AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bayer AG
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Lupin Pharmaceuticals, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Symbiomix Therapeutics, Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Mission Pharmacal Company
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development